pdf,smiles,doi,title,publisher,year,access,compound_id,target_type,target_relation,target_value,target_units,bacteria,bacteria_name_unified,bacteria_info,page_bacteria,origin_bacteria,section_bacteria,subsection_bacteria,page_target,origin_target,section_target,subsection_target,column_prop,line_prop,page_scaffold,origin_scaffold,section_scaffold,subsection_scaffold,page_residue,origin_residue,section_residue
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,1,pMIC,'=',"5,52",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,2,pMIC,'=',"6,16",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,3,pMIC,'=',"5,76",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,4,pMIC,'=',"5,59",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,5,pMIC,'=',"5,86",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,6,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,7,pMIC,'=',"5,29",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,8,pMIC,'=',"4,37",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,9,pMIC,'=',"5,03",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,10,pMIC,'=',"5,04",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,11,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,12,pMIC,'=',"4,77",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,13,pMIC,'=',"5,27",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,14,pMIC,'=',"4,37",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,15,pMIC,'=',"5,29",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,3,table 1,,,,,2,figure 1,,,3,table 1,
08927020601188528,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,16,pMIC,'=',"5,01",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,17,pMIC,'=',"5,22",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,18,pMIC,'=',"5,01",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,19,pMIC,'=',"4,37",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,20,pMIC,'=',"4,39",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,21,pMIC,'=',"5,86",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,22,pMIC,'=',"5,36",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,23,pMIC,'=',"4,75",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,24,pMIC,'=',"4,41",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,25,pMIC,'=',"5,03",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,26,pMIC,'=',"5,25",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,27,pMIC,'=',5,mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,28,pMIC,'=',"5,05",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,29,pMIC,'=',"5,24",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,4,table 1,,,,,2,figure 1,,,4,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,30,pMIC,'=',"4,41",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,31,pMIC,'=',"4,71",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,32,pMIC,'=',"4,43",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,33,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,34,pMIC,'=',"4,94",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,35,pMIC,'=',"4,64",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,36,pMIC,'=',"4,71",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,37,pMIC,'=',"4,96",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,38,pMIC,'=',"5,22",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,39,pMIC,'=',"4,95",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,40,pMIC,'=',"5,53",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,41,pMIC,'=',"5,58",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,42,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,43,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,44,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,5,table 1,,,,,2,figure 1,,,5,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,45,pMIC,'=',"5,86",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,46,pMIC,'=',"4,98",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,47,pMIC,'=',"4,69",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,48,pMIC,'=',"4,96",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,49,pMIC,'=',"4,68",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,50,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,51,pMIC,'=',"4,92",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,52,pMIC,'=',"5,86",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,53,pMIC,'=',"4,92",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,54,pMIC,'=',"4,39",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,55,pMIC,'=',"4,36",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,56,pMIC,'=',"4,96",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,57,pMIC,'=',"4,37",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,58,pMIC,'=',"4,96",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,6,table 1,,,,,2,figure 1,,,6,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,59,pMIC,'=',"4,64",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,60,pMIC,'=',"4,47",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,61,pMIC,'=',"4,64",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,62,pMIC,'=',"4,97",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,63,pMIC,'=',"4,32",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,64,pMIC,'=',"5,23",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,65,pMIC,'=',"4,66",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,66,pMIC,'=',"4,98",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,67,pMIC,'=',"5,26",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,68,pMIC,'=',"4,93",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,69,pMIC,'=',"5,53",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3n[nH]c(=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,70,pMIC,'=',"5,55",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,71,pMIC,'=',"5,55",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,72,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,7,table 1,,,,,2,figure 1,,,7,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,73,pMIC,'=',"5,57",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,74,pMIC,'=',"5,28",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,75,pMIC,'=',"5,63",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,76,pMIC,'=',"4,71",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,77,pMIC,'=',"5,61",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,78,pMIC,'=',"5,27",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,79,pMIC,'=',"5,6",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,80,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,81,pMIC,'=',"5,88",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,82,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CCC(C)=NO)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,83,pMIC,'=',"5,32",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,84,pMIC,'=',"4,71",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,85,pMIC,'=',"5,03",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,86,pMIC,'=',"4,66",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,8,table 1,,,,,2,figure 1,,,8,table 1,
08927020601188528,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,87,pMIC,'=',"4,98",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,89,pMIC,'=',"6,25",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,90,pMIC,'=',"5,88",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,91,pMIC,'=',"5,9",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn[nH]3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,92,pMIC,'=',"4,9",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccnn3C)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,93,pMIC,'=',"5,52",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccnn3CCO)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,94,pMIC,'=',"4,36",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccnn3CCC#N)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,95,pMIC,'=',"4,37",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,C=CCn1nccc1-c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,96,pMIC,'=',"4,65",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn(C)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,97,pMIC,'=',"4,62",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn(CCO)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,98,pMIC,'=',"4,36",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn(CCC#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,99,pMIC,'=',"4,97",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,Materials and methods,Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,C=CCn1ccc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,100,pMIC,'=',"4,65",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,9,table 1,,,,,2,figure 1,,,9,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn(CC#N)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,101,pMIC,'=',"5,25",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,COC(=O)n1ccc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,102,pMIC,'=',"4,67",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3ccn(C(C)=O)n3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,103,pMIC,'=',"4,97",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cn[nH]c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,104,pMIC,'=',"5,2",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cnn(CCF)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,105,pMIC,'=',"5,26",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cnn(C(C)=O)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,106,pMIC,'=',"5,28",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cnn(Cc4ccccc4)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,107,pMIC,'=',"4,71",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,C=CCn1cc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)cn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,108,pMIC,'=',"4,95",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cnn(C)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,109,pMIC,'=',"5,52",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CCn1cc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)cn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,110,pMIC,'=',"4,94",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(-c3cnn(CC#N)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,111,pMIC,'=',"5,25",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CNC(=O)n1cc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)cn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,112,pMIC,'=',"5,59",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=S)NC[C@H]1CN(c2ccc(-c3cn[nH]c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,113,pMIC,'=',"5,83",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=S)NC[C@H]1CN(c2ccc(-c3cnn(C)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,114,pMIC,'=',"5,84",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CCn1cc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)cn1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,115,pMIC,'=',"5,56",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,10,table 1,,,,,2,figure 1,,,10,table 1,
08927020601188528,CC(=S)NC[C@H]1CN(c2ccc(-c3cnn(CC#N)c3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,116,pMIC,'=',"6,17",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,11,table 1,,,,,2,figure 1,,,11,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,linezolid,pMIC,'=',"4,93",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,11,table 1,,,,,2,figure 1,,,11,table 1,
08927020601188528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1080/08927020601188528,QSAR study of oxazolidinone antibacterial agents using artificial neural networks,Informa UK Limited,2007,0,Eperezolid,pMIC,'=',"4,99",mol/l,methicillin-susceptible S. aureus,Staphylococcus aureus,Methicillin susceptible,2,text,2. Materials and methods,2.1 Data set and descriptor calculation,11,table 1,,,,,2,figure 1,,,11,table 1,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(/C=C/c5ccccc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1a,MIC,'=',25,μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccc(C)cc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1b,MIC,'=',"12,5",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccc(C#N)cc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1c,MIC,'=',"6,25",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccc(F)cc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1d,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,COc1cccc(-c2cc(CN3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)on2)c1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1e,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,COc1ccc(-c2cc(CN3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)on2)cc1OC,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1f,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccc(Oc6ccccc6)cc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1g,MIC,'=',100,μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccccn5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1h,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccccc5S)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1i,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,COc1cc(CN2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)on1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1j,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(Cc4cc(-c5ccc(Cl)cc5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,1k,MIC,'=',50,μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4ccno4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2a,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,COc1cc(C(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)on1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2b,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(OCCF)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2c,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C#N)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2d,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C(F)(F)F)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2e,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C(N)=O)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2f,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(COC(=O)N(C)C)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2g,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(-c5ccccc5S)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2h,MIC,'=',"0,78",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,4,table 2,,,,,4,image,Results and Discussion,,4,table 2,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2i,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C(=O)O)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2j,MIC,'=',100,μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(Cl)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2l,MIC,'=',"0,78",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(Br)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2m,MIC,'=',"0,78",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(C(=O)N(C)C)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2n,MIC,'=',"3,12",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(COC(N)=O)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2o,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(-c5nccs5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2p,MIC,'=',"0,39",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(-c5csnn5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2q,MIC,'=',"0,78",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cc(-c5cnsn5)no4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,2r,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4cccs4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,5,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0960-894x(99)00474-6,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)c4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/s0960-894x(99)00474-6,3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis,Elsevier BV,1999,0,6,MIC,'=',"1,56",μg/mL,methicillin-resistant Staphylococcus aureus 88 (MRSA 88),Staphylococcus aureus,Methicillin resistant  88,2,text,Results and Discussion,,5,table 3,,,,,4,image,Results and Discussion,,5,table 3,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccccc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,1,pMIC,'=',"0,263",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,2,pMIC,'=',"0,893",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,3,pMIC,'=',"1,817",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,4,pMIC,'=',"2,14",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,5,pMIC,'=',"1,516",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,6,pMIC,'=',"2,742",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(Cl)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,7,pMIC,'=',"2,191",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(Br)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,8,pMIC,'=',"1,948",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(I)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,9,pMIC,'=',"1,099",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(C)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,10,pMIC,'=',"2,463",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(F)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,11,pMIC,'=',"2,469",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(O)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,12,pMIC,'=',"2,165",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCC(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,13,pMIC,'=',"2,463",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)Cc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,14,pMIC,'=',"1,861",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCC(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,15,pMIC,'=',"3,085",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)C(C)C)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,16,pMIC,'=',"2,483",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)CF)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,17,pMIC,'=',"2,168",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)CCl)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,18,pMIC,'=',"2,793",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)CC#N)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,19,pMIC,'=',"1,576",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NCC(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,20,pMIC,'=',"1,62",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)COC(C)=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,21,pMIC,'=',"2,825",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,COC(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,22,pMIC,'=',"2,165",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C=NO)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,23,pMIC,'=',"1,239",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(/C(C)=N\O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,24,pMIC,'=',"1,862",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCC(O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,25,pMIC,'=',"0,961",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCC(O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,26,pMIC,'=',"1,282",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)(C)O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,27,pMIC,'=',"2,165",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(O)C(C)C)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,28,pMIC,'=',"1,884",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc([N+](=O)[O-])cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,29,pMIC,'=',"2,145",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(N)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,30,pMIC,'=',"0,289",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCN(CC)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,31,pMIC,'=',"1,582",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCCOc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,32,pMIC,'=',"1,583",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(F)(F)F)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,33,pMIC,'=',"1,577",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CSc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,34,pMIC,'=',"1,846",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCSc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,35,pMIC,'=',"2,469",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(S(C)=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,36,pMIC,'=',"1,87",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(S(C)=O)c([N+](=O)[O-])c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,37,pMIC,'=',"1,63",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCS(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,38,pMIC,'=',"1,288",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCS(=O)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,39,pMIC,'=',"1,006",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2cccc(F)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,40,pMIC,'=',"0,897",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(S(C)=O)c(C)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,41,pMIC,'=',"1,589",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C)c(C)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,42,pMIC,'=',"1,516",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(S(N)(=O)=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,43,pMIC,'=',"0,991",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2cccc(C)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,44,pMIC,'=',"0,89",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2cccc(Cl)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,45,pMIC,'=',"0,623",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2cccc(Br)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,46,pMIC,'=',"1,292",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCc1cccc(N2C[C@H](CNC(C)=O)OC2=O)c1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,47,pMIC,'=',"1,215",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,COc1cccc(N2C[C@H](CNC(C)=O)OC2=O)c1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,48,pMIC,'=',"0,616",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CSc1cccc(N2C[C@H](CNC(C)=O)OC2=O)c1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,49,pMIC,'=',"1,244",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc3ccccc3c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,50,pMIC,'=',"1,852",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,C=Cc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,51,pMIC,'=',"1,813",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,C#Cc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,52,pMIC,'=',"1,208",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,53,pMIC,'=',"1,843",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CCCSc1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,54,pMIC,'=',"1,586",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(S(C)(=O)=O)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,55,pMIC,'=',"1,893",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(=O)CBr)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,56,pMIC,'=',"1,948",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(N(C)C)cc2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,57,pMIC,'=',"1,239",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(N)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,59,pMIC,'=',"1,862",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
s0968-0896(01)00186-9,CC(=O)NC[C@H]1CN(c2cccc(I)c2)C(=O)O1,10.1016/s0968-0896(01)00186-9,Three-dimensional quantitative structure–activity relationship (3D-QSAR) of 3-aryloxazolidin-2-one antibacterials,Elsevier BV,2001,0,60,pMIC,'=',"0,75",mM/l,Staphylococcus aureus SFCO-1a,Staphylococcus aureus,SFCO-1a,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CCC[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,21,MIC,'=',"0,25",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CCC[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,21,MIC,'=',"0,25",μg/mL,Penicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant and quinolone resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CCC[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,21,MIC,'=',"0,25",μg/mL,Vancomycin resistant and quinolone resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant and quinolone resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CN(C#N)C[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,22,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CN(C#N)C[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,22,MIC,'=',"0,25",μg/mL,Penicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant and quinolone resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C3(C#N)[C@@H]4CN(C#N)C[C@@H]43)cc2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,22,MIC,'=',"0,25",μg/mL,Vancomycin resistant and quinolone resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant and quinolone resistant,4,table 1,,,4,table 1,,,,,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,NC1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,47,MIC,'=',"0,25",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,47,MIC,'=',"0,25",μg/mL,Penicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,47,MIC,'=',1,μg/mL,Vancomycin resistant and quinolone resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@@H]1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,48,MIC,'=',"0,06",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@@H]1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,48,MIC,'=',"0,25",μg/mL,Penicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@@H]1[C@H]2CN(c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)C[C@@H]12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,48,MIC,'=',"0,25",μg/mL,Vancomycin resistant and quinolone resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@]1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,49,MIC,'=',"0,06",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@]1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,49,MIC,'=',"0,06",μg/mL,Penicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,N#C[C@]1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,49,MIC,'=',"0,06",μg/mL,Vancomycin resistant and quinolone resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant and quinolone resistant,8,table 2,,,8,table 2,,,,,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,63,MIC,'=',5,μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,63,MIC,'=',5,μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(C(C)=O)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,63,MIC,'=',10,μg/mL,Staphylococcus epidermis,Staphylococcus epidermidis,,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(-c3csc(CC#N)n3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,64,MIC,'=',20,μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(-c3csc(CC#N)n3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,64,MIC,'=',10,μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(-c3csc(CC#N)n3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,64,MIC,'=',20,μg/mL,Staphylococcus epidermis,Staphylococcus epidermidis,,10,table 3,,,10,table 3,,,,,9,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)N1CCN(c2ccc(N3C[C@H](CNC(=S)c4ccoc4)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,77,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,11,table 5,,,11,table 5,,,,,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)N1CCN(c2ccc(N3C[C@H](CNC(=S)c4ccoc4)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,77,MIC,'=',"0,5",μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,11,table 5,,,11,table 5,,,,,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)N1CCN(c2ccc(N3C[C@H](CNC(=S)c4ccoc4)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,77,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus epidermidis,Staphylococcus epidermidis,Methicillin resistant,11,table 5,,,11,table 5,,,,,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)N1CCN(c2ccc(N3C[C@H](CNC(=S)c4ccoc4)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,77,MIC,'=',"0,5",μg/mL,Penicillin resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,11,table 5,,,11,table 5,,,,,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',1,μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,11,table 5,,,11,table 5,,,,,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',2,μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,11,table 5,,,11,table 5,,,,,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',1,μg/mL,Methicillin resistant Staphylococcus epidermidis,Staphylococcus epidermidis,Methicillin resistant,11,table 5,,,11,table 5,,,,,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',2,μg/mL,Penicillin resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,11,table 5,,,11,table 5,,,,,1,figure 1,,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,2",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,4",μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,4",μg/mL,Vancomycin resistant Enterococcus faecalis,Enterococcus faecalis,Vancomycin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,2",μg/mL,Vancomycin susceptible Enterococcus faecalis,Enterococcus faecalis,Vancomycin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,2",μg/mL,Vancomycin resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=CNC[C@H]1CN(c2ccc(-n3ccc(/C=N/O)c3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,120,MIC,'=',"0,2",μg/mL,Vancomycin susceptible Enterococcus faecium,Enterococcus faecium,Vancomycin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,4",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,4",μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,8",μg/mL,Vancomycin resistant Enterococcus faecalis,Enterococcus faecalis,Vancomycin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,8",μg/mL,Vancomycin susceptible Enterococcus faecalis,Enterococcus faecalis,Vancomycin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,4",μg/mL,Vancomycin resistant Enterococcus faecium,Enterococcus faecium,Vancomycin resistant,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCOC(OCC)c1cn(-c2ccc(N3C[C@H](CNC=O)OC3=O)cc2F)nn1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,121,MIC,'=',"0,4",μg/mL,Vancomycin susceptible Enterococcus faecium,Enterococcus faecium,Vancomycin susceptible,17,table 6,,,17,table 6,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)C6CC6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,125,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)C6CC6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,125,MIC,'=',"0,5",μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)C6CC6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,125,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus epidermidis,Staphylococcus epidermidis,Methicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)C6CC6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,125,MIC,'=',"0,5",μg/mL,Penicillin resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)c6cccnc6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,126,MIC,'=',"0,06",μg/mL,Methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)c6cccnc6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,126,MIC,'=',1,μg/mL,Methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)c6cccnc6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,126,MIC,'=',"0,5",μg/mL,Methicillin resistant Staphylococcus epidermidis,Staphylococcus epidermidis,Methicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccc2cc(C(=O)NC[C@H]3CN(c4ccc(N5CCN(C(=O)c6cccnc6)CC5)c(F)c4)C(=O)O3)c(C)nc2c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,126,MIC,'=',1,μg/mL,Penicillin resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,17,table 7,,,17,table 7,,,,,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CCCCCCC/C(C)=C/C(=O)/C=C1\NC(=O)C(CCCC)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,16,MIC,'=',"1,04",μg/mL,methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,3,text,MODIFICATIONS IN THE REGION A WITH C5,,3,text,MODIFICATIONS IN THE REGION A WITH C5,,right,3,3,image,MODIFICATIONS IN THE REGION A WITH C5,,,,
187152108785908820,CCCCCCC/C(C)=C/C(=O)/C=C1\NC(=O)C(CCCC)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,16,MIC,'=',"0,88",μg/mL,methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,3,text,MODIFICATIONS IN THE REGION A WITH C5,,3,text,MODIFICATIONS IN THE REGION A WITH C5,,right,4,3,image,MODIFICATIONS IN THE REGION A WITH C5,,,,
187152108785908820,CCCCCCC/C(C)=C/C(=O)/C=C1\NC(=O)C(CCCC)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,16,MIC,'=',"1,83",μg/mL,vancomycin resistant Enterococcus faecalis,Enterococcus faecalis,Vancomycin resistant,3,text,MODIFICATIONS IN THE REGION A WITH C5,,3,text,MODIFICATIONS IN THE REGION A WITH C5,,right,5,3,image,MODIFICATIONS IN THE REGION A WITH C5,,,,
187152108785908820,CCCCCCC/C(C)=C/C(=O)/C=C1\NC(=O)C(CCCC)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,16,MIC,'=',1,μg/mL,vancomycin susceptible Enterococcus faecalis,Enterococcus faecalis,Vancomycin susceptible,3,text,MODIFICATIONS IN THE REGION A WITH C5,,3,text,MODIFICATIONS IN THE REGION A WITH C5,,right,6,3,image,MODIFICATIONS IN THE REGION A WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)OCC(=NC#N)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,19,MIC,'=',1,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,24,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)OCC(=NC#N)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,19,MIC,'=',"0,5",μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,25,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)OCC(=NC#N)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,19,MIC,'=',1,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,26,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CON=c1sc2cc(N3C[C@H](CNC(C)=O)OC3=O)ccc2n1C,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,20,MIC,'=',4,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,28,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CON=c1sc2cc(N3C[C@H](CNC(C)=O)OC3=O)ccc2n1C,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,20,MIC,'=',2,μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,29,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CON=c1sc2cc(N3C[C@H](CNC(C)=O)OC3=O)ccc2n1C,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,20,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,3,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,30,3,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCC/C(=C/c2ccc(F)cc2)C3=O)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,26a,MIC,'=',2,μg/mL,Haemophilus influenza,Haemophilus influenzae,,4,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,4,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,14,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCC/C(=C\c2ccsc2)C3=O)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,26b,MIC,'=',2025-02-01 00:00:00,μg/mL,Haemophilus influenza,Haemophilus influenzae,,4,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,4,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,right,15,4,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CC(=O)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,27,MIC,'=',4,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,1,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CC(=O)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,27,MIC,'=',1,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,2,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CC(=O)N3C)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,27,MIC,'=',2,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,2,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)ccc21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,31,MIC,'=',2,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,20,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)ccc21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,31,MIC,'=',2,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,21,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC(C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)ccc21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,31,MIC,'=',4,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,21,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC[C@H](C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)cc(F)c21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,32,MIC,'=',2,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,20,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC[C@H](C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)cc(F)c21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,32,MIC,'=',2,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,21,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,CC[C@H](C)n1ncc2cc(N3C[C@H](Cn4ccnn4)OC3=O)cc(F)c21,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,32,MIC,'=',4,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,5,text,MODIFICATIONS IN THE REGION B AND AT THE C5,,left,21,5,image,MODIFICATIONS IN THE REGION B AND AT THE C5,,,,
187152108785908820,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)n1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,51,MIC,'=',"0,25",μg/mL,methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,13,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)n1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,51,MIC,'=',"0,125",μg/mL,vancomycin resistant Enterococci,Enterococci,Vancomycin resistant,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,14,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4nccn4)nc3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,52,MIC,'=',"0,25",μg/mL,methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,13,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4nccn4)nc3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,52,MIC,'=',"0,125",μg/mL,vancomycin resistant Enterococci,Enterococci,Vancomycin resistant,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,14,7,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,53,MIC,'=',"0,125",μg/mL,methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,22,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,53,MIC,'=',"0,125",μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,22,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,53,MIC,'=',"0,06",μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,23,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc(C=C5SC(=O)NC5=O)cc4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,54,MIC,'=',"0,5",μg/mL,Staphylococcus aureus,Staphylococcus aureus,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,29,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc(C=C5SC(=O)NC5=O)cc4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,54,MIC,'=',"0,5",μg/mL,Staphylococcus epidermidis,Staphylococcus epidermidis,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,30,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(c4ccc(C=C5SC(=O)NC5=O)cc4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,54,MIC,'=',"0,5",μg/mL,Enterococcus faecalis,Enterococcus faecalis,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,7,text,MODIFICATIONS IN THE REGION C WITH C5,,right,31,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Br.CC(=O)NC[C@H]1CN(c2ccc(C3Cc4cc(O)c(O)cc4CN3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,56,MIC,>,64,μg/mL,methicillin susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,8,text,MODIFICATIONS IN THE REGION C WITH C5,,8,text,MODIFICATIONS IN THE REGION C WITH C5,,left,6,8,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCN(C/C(N)=N/O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,69,MIC,'=',"0,5",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,13,10,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCN(C/C(N)=N/O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,69,MIC,'=',4,μg/mL,Haemophilius influenza,Haemophilus influenzae,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,14,10,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C/C(N)=N/O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,71,MIC,'=',"0,5",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,13,10,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C/C(N)=N/O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,71,MIC,'=',4,μg/mL,Haemophilius influenza,Haemophilus influenzae,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,14,10,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',8,μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,15,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',8,μg/mL,Haemophilius influenza,Haemophilus influenzae,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,10,text,MODIFICATIONS IN THE REGION C WITH C5,,left,15,1,figure 1,,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CCNC(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,78,MIC,'=',4,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,left,7,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CCNC(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,78,MIC,'=',2,μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,1,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CCNC(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,78,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,2,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CNC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,79,MIC,'=',2,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,6,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CNC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,79,MIC,'=',1,μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,7,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CNC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,79,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,8,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,80,MIC,'=',2,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,6,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,80,MIC,'=',1,μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,7,11,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2ccc(N3CCCS(=O)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,80,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,8,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)n1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,81,MIC,'=',"0,25",μg/mL,methicillin resistant and quinoline resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,13,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)n1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,81,MIC,'=',"0,25",μg/mL,methicillin sensitive and quinolone sensitive Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,11,text,MODIFICATIONS IN THE REGION C WITH C5,,11,text,MODIFICATIONS IN THE REGION C WITH C5,,right,14,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)n1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,81,MIC,'=',"0,5",μg/mL,linezolid resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Linezolid resistant,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,2,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NCC1CN(c2ccc(N3C[C@@H]4OCCN(C)[C@H]4C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,82,MIC,'=',4,μg/mL,methicillin resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,5,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NCC1CN(c2ccc(N3C[C@@H]4OCCN(C)[C@H]4C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,82,MIC,'=',2,μg/mL,vancomycin resistant Enterococci,Enterococci,Vancomycin resistant,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,7,12,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',2,μg/mL,vancomycin resistant Enterococci,Enterococci,Vancomycin resistant,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,6,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',16,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,7,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,1,MIC,'=',"0,5",μg/mL,Streptococcus pyogens,Streptococcus pyogenes,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,12,text,MODIFICATIONS IN THE REGION C WITH C5,,left,22,1,figure 1,,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,112a,MIC,'=',8,μg/mL,Haemophilus influenzae,Haemophilus influenzae,,15,text,MODIFICATIONS IN THE REGION C WITH C5,,15,text,MODIFICATIONS IN THE REGION C WITH C5,,left,54,15,image,MODIFICATIONS IN THE REGION C WITH C5,,15,image,MODIFICATIONS IN THE REGION C WITH C5
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,112a,MIC,'=',2,μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,15,text,MODIFICATIONS IN THE REGION C WITH C5,,15,text,MODIFICATIONS IN THE REGION C WITH C5,,left,55,15,image,MODIFICATIONS IN THE REGION C WITH C5,,15,image,MODIFICATIONS IN THE REGION C WITH C5
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,112a,MIC,'=',"0,25",μg/mL,sensitive Mycobacterium tuberculosis,Mycobacterium tuberculosis,Sensitive,15,text,MODIFICATIONS IN THE REGION C WITH C5,,15,text,MODIFICATIONS IN THE REGION C WITH C5,,left,59,15,image,MODIFICATIONS IN THE REGION C WITH C5,,15,image,MODIFICATIONS IN THE REGION C WITH C5
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,112a,MIC,'=',1,μg/mL,multi-drug resistant Mycobacterium tuberculosis,Mycobacterium tuberculosis,Multi-drug resistant,15,text,MODIFICATIONS IN THE REGION C WITH C5,,15,text,MODIFICATIONS IN THE REGION C WITH C5,,left,59,15,image,MODIFICATIONS IN THE REGION C WITH C5,,15,image,MODIFICATIONS IN THE REGION C WITH C5
187152108785908820,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCCOCC2)c(F)c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,122,MIC,'=',4,μg/mL,susceptible Staphylococcus aureus,Staphylococcus aureus,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,5,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCCOCC2)c(F)c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,122,MIC,'=',1,μg/mL,susceptible Streptococcus pyogens,Streptococcus pyogenes,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,6,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCCOCC2)c(F)c1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,122,MIC,'=',2,μg/mL,susceptible Streptococcus pneumoniae,Streptococcus pneumoniae,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,7,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cc1cc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)on1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,123,MIC,'=',"0,5",μg/mL,methicillin sensitive and quinolone sensitive Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,13,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cc1cc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)on1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,123,MIC,'=',"0,25",μg/mL,methicillin resistant and quinolone resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Methicillin resistant,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,14,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,Cc1cc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)on1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,123,MIC,'=',1,μg/mL,methicillin resistant and quinolone resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,16,text,MODIFICATIONS IN THE REGION C WITH C5,,16,text,MODIFICATIONS IN THE REGION C WITH C5,,right,15,16,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,127,MIC,'=',8,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,9,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,127,MIC,'=',8,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,10,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,127,MIC,'=',8,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,11,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,128,MIC,'=',4,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,9,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,128,MIC,'=',8,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,11,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,NC(=O)[C@H]1CN(c2cc(F)c(N3CC(F)(F)C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,128,MIC,'=',16,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,left,12,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,131,MIC,'=',2,μg/mL,Staphylococcus aureus,Staphylococcus aureus,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,right,3,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,131,MIC,'=',2,μg/mL,Enterococcus faecalis,Enterococcus faecalis,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,17,text,MODIFICATIONS IN THE REGION C WITH C5,,right,3,17,image,MODIFICATIONS IN THE REGION C WITH C5,,,,
187152108785908820,O=C(O)c1cn(C2CC2)c2c3c(c(F)cc2c1=O)N1C[C@](O)(COc2ccc(N4C[C@@H](Cn5ccnn5)OC4=O)cc2F)C[C@@H]1CO3,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,134,MIC,<=,"0,063",μg/mL,Staphylococcus aureus,Staphylococcus aureus,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,left,15,18,image,HYBRID MOLECULES,,,,
187152108785908820,O=C(O)c1cn(C2CC2)c2c3c(c(F)cc2c1=O)N1C[C@](O)(COc2ccc(N4C[C@@H](Cn5ccnn5)OC4=O)cc2F)C[C@@H]1CO3,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,134,MIC,<=,"0,063",μg/mL,Streptococcus pneumonia,Streptococcus pneumoniae,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,left,15,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(OC[C@]3(O)C[C@@H]4COc5c(c(F)cc6c(=O)c(C(=O)O)cn(C7CC7)c56)N4C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,135,MIC,<=,"0,063",μg/mL,Staphylococcus aureus,Staphylococcus aureus,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,left,15,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc(OC[C@]3(O)C[C@@H]4COc5c(c(F)cc6c(=O)c(C(=O)O)cn(C7CC7)c56)N4C3)c(F)c2)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,135,MIC,<=,"0,063",μg/mL,Streptococcus pneumonia,Streptococcus pneumoniae,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,left,15,18,image,HYBRID MOLECULES,,,,
187152108785908820,COc1c(N2CCc3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3CC2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,136,MIC,'=',"0,25",μg/mL,Staphylococcus aureus,Staphylococcus aureus,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,1,18,image,HYBRID MOLECULES,,,,
187152108785908820,COc1c(N2CCc3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3CC2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,136,MIC,'=',"0,06",μg/mL,Enterococcus faecalis,Enterococcus faecalis,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,2,18,image,HYBRID MOLECULES,,,,
187152108785908820,COc1c(N2CCc3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3CC2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,136,MIC,'=',"0,06",μg/mL,Haemophilus influenza,Haemophilus influenzae,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,2,18,image,HYBRID MOLECULES,,,,
187152108785908820,COc1c(N2CCc3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3CC2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,136,MIC,'=',"0,13",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,3,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCN(c2c(F)cc4c(=O)c(C(=O)O)cn(C5CC5)c4c2Cl)CC3)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,137,MIC,'=',"0,25",μg/mL,Staphylococcus aureus,Staphylococcus aureus,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,1,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCN(c2c(F)cc4c(=O)c(C(=O)O)cn(C5CC5)c4c2Cl)CC3)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,137,MIC,'=',"0,06",μg/mL,Enterococcus faecalis,Enterococcus faecalis,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,2,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCN(c2c(F)cc4c(=O)c(C(=O)O)cn(C5CC5)c4c2Cl)CC3)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,137,MIC,'=',"0,06",μg/mL,Haemophilus influenza,Haemophilus influenzae,,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,2,18,image,HYBRID MOLECULES,,,,
187152108785908820,CC(=O)NC[C@H]1CN(c2ccc3c(c2)CCN(c2c(F)cc4c(=O)c(C(=O)O)cn(C5CC5)c4c2Cl)CC3)C(=O)O1,10.2174/187152108785908820,Oxazolidinone Antibacterials and Our Experience,Bentham Science Publishers Ltd.,2008,0,137,MIC,'=',"0,13",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,18,text,HYBRID MOLECULES,,18,text,HYBRID MOLECULES,,right,3,18,image,HYBRID MOLECULES,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,'=',125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,'=',"1,17",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,'=',"1,17",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,'=',"1,17",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,2,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,'=',"1,17",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,'=',"1,17",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CS(=O)(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)c4ccc([N+](=O)[O-])o4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3a,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,'=',"2,34",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3b,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,CC(=O)c1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3c,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,'=',"18,75",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,'=',75,μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,'=',125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,'=',75,μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3d,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,>,125,μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,>,125,μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,COc1ccc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)cc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3e,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,'=',"9,36",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,'=',"9,36",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(Cl)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3f,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,'=',125,μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,'=',125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,'=',75,μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3g,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,'=',"18,75",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3h,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,'=',"18,75",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,Cc1cc(S(=O)(=O)N2CCN(c3ccc(N4C[C@@H](CNC(O)c5ccc([N+](=O)[O-])o5)OC4=O)cc3F)CC2)ccc1F,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3i,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,'=',"2,34",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,'=',"9,36",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,>,125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C1O[C@H](CNC(O)c2ccc([N+](=O)[O-])o2)CN1c1ccc(N2CCN(S(=O)(=O)c3ccnc4ccccc34)CC2)c(F)c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,3j,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 1 (caption),,,4,table 1,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,'=',"9,36",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,'=',75,μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,'=',"3,37",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)C(=Cc1ccccc1)c1ccccc1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4a,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,'=',"18,75",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1coc2ccccc12,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4b,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,'=',"2,34",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1)c1cnccn1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4c,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,'=',"2,34",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(Cl)c(C(=O)NC[C@@H]3CN(c4ccc(N5CCSCC5)c(F)c4)C(=O)O3)sc2c1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4d,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,'=',"2,34",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,O=C(C=Cc1ccc(-c2ccc(Cl)cc2)o1)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4e,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,'=',"18,75",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCSCC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4f,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,'=',"9,36",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,'=',75,μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,>,125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,'=',75,μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(C(=O)NC[C@@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4g,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,'=',"18,75",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,'=',"18,75",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cnccn4)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4h,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,'=',"37,5",μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,'=',"4,68",μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,'=',"37,5",μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,'=',"4,68",μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,Cc1ccc2c(c1)C=C(C(=O)NC[C@@H]1CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O1)[N]2,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4i,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Bacillus subtilis MTCC 121,Bacillus subtilis,MTCC 121,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Staphylococcus aureus MLS-16 MTCC 2940,Staphylococcus aureus,MTCC 2940,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Staphylococcus aureus MTCC 96,Staphylococcus aureus,MTCC 96,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Micrococcus luteus MTCC 2470,Micrococcus luteus,MTCC 2470,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Pseudomonas aeruginosa MTCC 2453,Pseudomonas aeruginosa,MTCC 2453,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Klebsiella planticola MTCC 530,Klebsiella planticola,MTCC 530,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
ph16040516,CC(C)(C)OC(=O)N1CCN(c2ccc(N3C[C@@H](CNC(=O)c4cccnc4Cl)OC3=O)cc2F)CC1,10.3390/ph16040516,Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones,MDPI AG,2023,1,4j,MIC,>,125,μg/mL,Escherichia coli MTCC 739,Escherichia coli,MTCC 739,4,table 2 (caption),,,4,table 2,,,,,3,figure 2,,,,,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ncc(N)n4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2a,MIC,>,8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ncc(N)n4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2a,MIC,>,8,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ncc(N)n4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2a,MIC,>,8,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C/n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2b,MIC,'=',1,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C/n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2b,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C/n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2b,MIC,'=',4,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C(\C)n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2c,MIC,'=',1,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C(\C)n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2c,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(/N=C(\C)n4c([N+](=O)[O-])cnc4C)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2c,MIC,'=',4,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])o4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2d,MIC,'=',"0,25",μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])o4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2d,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])o4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2d,MIC,'=',1,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2e,MIC,'=',"0,25",μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2e,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])s4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2e,MIC,'=',2,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4c(Cl)cccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2f,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4c(Cl)cccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2f,MIC,'=',8,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4c(Cl)cccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2f,MIC,'=',8,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2g,MIC,'=',2,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2g,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccccc4[N+](=O)[O-])CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2g,MIC,'=',2,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4cccc([N+](=O)[O-])c4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2h,MIC,'=',2,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4cccc([N+](=O)[O-])c4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2h,MIC,'=',1,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4cccc([N+](=O)[O-])c4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2h,MIC,'=',2,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2i,MIC,'=',4,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2i,MIC,'=',4,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(N=Cc4ccc([N+](=O)[O-])cc4)CC3)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,2i,MIC,'=',4,μg/mL,"VRE, vancomycin-resistant Enterococcus",Enterococci,Vancomycin resistant,4,figure 3 (caption),,,4,figure 3,,,,,4,figure 3,,,4,figure 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10a,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10a,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10a,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10a,MIC,'=',4,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10a,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10b,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10b,MIC,<,1,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10b,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10b,MIC,'=',2,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10b,MIC,<,1,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10c,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10c,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10c,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10c,MIC,'=',2,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10c,MIC,<,1,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10d,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10d,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10d,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10d,MIC,'=',4,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10d,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CNC(=O)C(F)(F)F)OC5=O)cc4F)ccc3N3COCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10e,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CNC(=O)C(F)(F)F)OC5=O)cc4F)ccc3N3COCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10e,MIC,'=',8,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CNC(=O)C(F)(F)F)OC5=O)cc4F)ccc3N3COCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10e,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CNC(=O)C(F)(F)F)OC5=O)cc4F)ccc3N3COCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10e,MIC,'=',8,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CNC(=O)C(F)(F)F)OC5=O)cc4F)ccc3N3COCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10e,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10f,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10f,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10f,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10f,MIC,'=',4,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10f,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10g,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10g,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10g,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10g,MIC,'=',2,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10g,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCOC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10h,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCOC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10h,MIC,'=',8,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCOC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10h,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCOC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10h,MIC,'=',8,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CCOC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3CCCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10h,MIC,'=',8,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COS(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10i,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COS(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10i,MIC,'=',32,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COS(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10i,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COS(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10i,MIC,'=',16,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COS(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NC(=O)NC3=O)C3COCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10i,MIC,'=',32,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCOCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10j,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCOCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10j,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCOCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10j,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCOCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10j,MIC,'=',4,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCOCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10j,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10k,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10k,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10k,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10k,MIC,'=',2,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10k,MIC,<,1,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10l,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10l,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10l,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10l,MIC,'=',2,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,O=C1NC(=O)C2(Cc3cc(-c4ccc(N5C[C@H](CO)OC5=O)cc4F)ccc3N3CCCC32)C(=O)N1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10l,MIC,<,1,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NNC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10m,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NNC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10m,MIC,'=',8,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NNC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10m,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NNC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10m,MIC,'=',8,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)CC3(C(=O)NNC3=O)C3CCCN43)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10m,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)C1(C(=O)OC)Cc2cc(-c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)ccc2N2CCOCC21,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10n,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 29 213,Staphylococcus aureus,ATCC 29213,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)C1(C(=O)OC)Cc2cc(-c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)ccc2N2CCOCC21,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10n,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus 562,Staphylococcus aureus,Methicillin resistant  562,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)C1(C(=O)OC)Cc2cc(-c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)ccc2N2CCOCC21,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10n,MIC,>,32,μg/mL,Linezolid-resistant Staphylococcus aureus ATCC 13 709 Smith,Staphylococcus aureus,Linezolid-resistant  ATCC 13 709,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)C1(C(=O)OC)Cc2cc(-c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)ccc2N2CCOCC21,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10n,MIC,'=',4,μg/mL,Staphylococcus epidermidis ATCC 12 228,Staphylococcus epidermidis,ATCC 12228,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,COC(=O)C1(C(=O)OC)Cc2cc(-c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)ccc2N2CCOCC21,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,10n,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus epidermidis ATCC 35 984,Staphylococcus epidermidis,Methicillin resistant,7,table 3 (caption),,,7,table 3,,,,,7,table 3,,,7,table 3,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CO)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23a,MIC,'=',64,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CO)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23a,MIC,'=',64,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CO)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23a,MIC,'=',128,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CO)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23a,MIC,'=',64,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23b,MIC,'=',32,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23b,MIC,'=',64,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23b,MIC,'=',64,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23b,MIC,'=',128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23c,MIC,'=',4,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23c,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23c,MIC,'=',8,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23c,MIC,'=',32,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CCCCc1cn(C[C@H]2CN(c3ccc(OCc4nc(C)c(C)nc4C)c(F)c3)C(=O)O2)nn1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23d,MIC,>,128,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CCCCc1cn(C[C@H]2CN(c3ccc(OCc4nc(C)c(C)nc4C)c(F)c3)C(=O)O2)nn1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23d,MIC,>,128,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CCCCc1cn(C[C@H]2CN(c3ccc(OCc4nc(C)c(C)nc4C)c(F)c3)C(=O)O2)nn1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23d,MIC,>,128,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CCCCc1cn(C[C@H]2CN(c3ccc(OCc4nc(C)c(C)nc4C)c(F)c3)C(=O)O2)nn1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23d,MIC,>,128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23e,MIC,'=',8,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23e,MIC,'=',16,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23e,MIC,'=',16,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23e,MIC,'=',32,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23f,MIC,'=',4,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23f,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23f,MIC,'=',4,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23f,MIC,'=',16,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23g,MIC,'=',8,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23g,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23g,MIC,'=',8,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23g,MIC,'=',16,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23h,MIC,'=',2,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23h,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23h,MIC,'=',4,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)CCl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23h,MIC,'=',8,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23i,MIC,'=',4,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23i,MIC,'=',8,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23i,MIC,'=',8,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23i,MIC,'=',16,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23j,MIC,'=',2,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23j,MIC,'=',4,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23j,MIC,'=',4,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23j,MIC,'=',8,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23k,MIC,'=',64,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23k,MIC,>,128,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23k,MIC,'=',128,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23k,MIC,>,128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23l,MIC,'=',32,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23l,MIC,'=',128,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23l,MIC,'=',32,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,COCC(=O)NC[C@H]1CN(c2ccc(OCc3nc(C)c(C)nc3C)c(F)c2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23l,MIC,'=',128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23m,MIC,'=',64,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23m,MIC,'=',128,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23m,MIC,'=',64,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23m,MIC,>,128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23n,MIC,'=',32,μg/mL,"MRSA, methicillin-resistant Staphylococcus aureus",Staphylococcus aureus,Methicillin resistant,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23n,MIC,'=',32,μg/mL,"S. aureus, Staphylococcus aureus",Staphylococcus aureus,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23n,MIC,'=',16,μg/mL,"S. epidermidis, Staphylococcus epidermidis",Staphylococcus epidermidis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,Cc1nc(C)c(COc2ccc(N3C[C@H](CNC(=O)c4ccco4)OC3=O)cc2F)nc1C,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,23n,MIC,'=',128,μg/mL,"E. faecalis, Enterococcus faecalis",Enterococcus faecalis,,10,table 4 (caption),,,10,table 4,,,,,10,table 4,,,10,table 4,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1OC(=O)N2[C]1COc1cc(N3CCSCC3)c(F)cc12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46a,MIC,'=',"0,03",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,O=C(NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12)C1CC1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46b,MIC,'=',"0,03",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,O=C(NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12)C1CCC1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46с,MIC,'=',"0,03",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,COC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46d,MIC,'=',"0,03",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,O=C1O[C@@H](CNc2ccon2)[C@@H]2COc3cc(N4CCSCC4)c(F)cc3N12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46e,MIC,'=',"0,03",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCS(=O)CC4)cc3OC[C@@H]12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46f,MIC,'=',"0,44",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4C5CCC4CSC5)cc3OC[C@@H]12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46g,MIC,'=',"0,92",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCC(F)(F)CC4)cc3OC[C@@H]12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46h,MIC,'=',"0,91",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CC5(COC5)C4)cc3OC[C@@H]12,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,46i,MIC,'=',"3,92",μg/mL,drug-resistant TB,Mycobacterium tuberculosis,Drug resistant,14,text,3.3. Tricyclic Fused Oxazolidinone Derivatives.,"3.3.3. Thiomorpholinyl Benzo[1,4]oxazinyl-oxazolidi-nones.",13,table 5,,,,,13,table 5,,,13,table 5,
acs.jmedchem.1c00480,O=C(NO)[C@@H]1CN(c2ccc(-c3ccccc3)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70a,MIC,'=',50,μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,CS(=O)(=O)CCCOc1ccc(C#Cc2ccc(N3C[C@@H](C(=O)NO)OC3=O)cc2)cc1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70b,MIC,'=',"6,25",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,CS(=O)(=O)CCOc1ccc(C#Cc2ccc(N3C[C@@H](C(=O)NO)OC3=O)cc2)cc1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70c,MIC,'=',50,μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,O=C(NO)[C@@H]1CN(c2ccc(C#Cc3ccccc3)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70d,MIC,'=',"0,625",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,O=C(NO)[C@@H]1CN(c2ccc(C#CC#Cc3ccccc3)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70e,MIC,'=',"0,12",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,Nc1ccc(C#CC#Cc2ccc(N3C[C@@H](C(=O)NO)OC3=O)cc2)cc1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70f,MIC,'=',"0,02",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,CNS(=O)(=O)c1ccc(C#CC#Cc2ccc(N3C[C@@H](C(=O)NO)OC3=O)cc2)cc1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70g,MIC,'=',"0,078",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,O=C(NO)[C@@H]1CN(c2ccc(C#CC#CC3CCCC3)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70h,MIC,'=',"0,015",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
acs.jmedchem.1c00480,O=C(NO)[C@@H]1CN(c2ccc(C#CC#CC3CC3)cc2)C(=O)O1,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs,American Chemical Society (ACS),2021,0,70i,MIC,'=',"0,03",μg/mL,E. coli,Escherichia coli,,16,figure 21,,,16,figure 21,,,,,16,figure 21,,,16,figure 21,
molecules27031103,CC(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11a,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CC(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11a,MIC,>,256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CC(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11a,MIC,'=',256,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CC(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11a,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCCC1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11b,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCCC1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11b,MIC,>,256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCCC1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11b,MIC,'=',128,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCCC1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11b,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCO1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11c,MIC,>,256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCO1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11c,MIC,>,256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCO1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11c,MIC,'=',128,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)C1CCCO1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11c,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(CCc1ccccc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11d,MIC,>,256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(CCc1ccccc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11d,MIC,>,256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(CCc1ccccc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11d,MIC,'=',256,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(CCc1ccccc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11d,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)c1cccnc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11e,MIC,>,256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)c1cccnc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11e,MIC,>,256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)c1cccnc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11e,MIC,>,256,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1)c1cccnc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11e,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(NC1CCCCC1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11f,MIC,'=',256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(NC1CCCCC1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11f,MIC,'=',128,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(NC1CCCCC1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11f,MIC,'=',128,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(NC1CCCCC1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11f,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(Nc1ccc(Cl)cc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11g,MIC,>,256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(Nc1ccc(Cl)cc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11g,MIC,'=',256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(Nc1ccc(Cl)cc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11g,MIC,>,256,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C(Nc1ccc(Cl)cc1)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11g,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11h,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11h,MIC,'=',128,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11h,MIC,'=',64,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCOCC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11h,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C1O[C@@H](COS(=O)(=O)c2ccccc2)CN1c1ccc(N2CCOCC2)nc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11i,MIC,>,256,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C1O[C@@H](COS(=O)(=O)c2ccccc2)CN1c1ccc(N2CCOCC2)nc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11i,MIC,'=',256,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C1O[C@@H](COS(=O)(=O)c2ccccc2)CN1c1ccc(N2CCOCC2)nc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11i,MIC,>,256,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,O=C1O[C@@H](COS(=O)(=O)c2ccccc2)CN1c1ccc(N2CCOCC2)nc1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,11i,MIC,>,256,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12a,MIC,'=',32,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12a,MIC,'=',32,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12a,MIC,'=',32,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12a,MIC,'=',16,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)c4ccc(C(F)(F)F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12b,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)c4ccc(C(F)(F)F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12b,MIC,'=',128,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)c4ccc(C(F)(F)F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12b,MIC,'=',128,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)c4ccc(C(F)(F)F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12b,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)CCc4ccccc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12c,MIC,'=',64,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)CCc4ccccc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12c,MIC,'=',32,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)CCc4ccccc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12c,MIC,'=',32,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)CCc4ccccc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12c,MIC,'=',32,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C=Cc4cccnc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12d,MIC,'=',32,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C=Cc4cccnc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12d,MIC,'=',64,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C=Cc4cccnc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12d,MIC,'=',64,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)C=Cc4cccnc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12d,MIC,'=',64,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12e,MIC,'=',32,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12e,MIC,'=',32,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12e,MIC,'=',16,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCC4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12e,MIC,'=',32,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12f,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12f,MIC,'=',128,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12f,MIC,'=',64,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12f,MIC,'=',64,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12g,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12g,MIC,'=',32,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12g,MIC,'=',32,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12g,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12h,MIC,'=',128,μg/mL,S. Aureus Atcc 25923,Staphylococcus aureus,ATCC 25923,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12h,MIC,'=',128,μg/mL,S. Pneumoniae Atcc 49619,Streptococcus pneumoniae,ATCC 49619,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12h,MIC,'=',128,μg/mL,B. Subtilis Bncc 109047,Bacillus subtilis,BNCC 109047,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
molecules27031103,CS(=O)(=O)OC[C@H]1CN(c2ccc(N3CCN(S(=O)(=O)c4ccc(F)cc4F)CC3)nc2)C(=O)O1,10.3390/molecules27031103,"Synthesis, Antibacterial and Anthelmintic Activity of Novel 3-(3-Pyridyl)-oxazolidinone-5-methyl Ester Derivatives",MDPI AG,2022,1,12h,MIC,'=',128,μg/mL,S. Epidermidis Bncc 186652,Staphylococcus epidermidis,BNCC 186652,3,table 1,,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5a,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5b,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,'=',"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,<,"0,125",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,'=',"0,5",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,'=',2,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5c,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',"0,5",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5d,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CF)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5e,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',2,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',4,μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',8,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,COCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5f,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(COC(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5g,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,'=',8,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,'=',8,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,'=',2,μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,'=',8,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,>,16,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CCOC(=O)c1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5h,MIC,'=',16,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',"0,5",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)CCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5i,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',2,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC#N)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5j,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,>,16,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CSCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5k,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',1,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',1,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CO)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5l,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',"0,5",μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',16,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(C(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5m,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',4,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',4,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',2,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC(N)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5n,MIC,'=',8,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',2,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',2,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CC/C(C)=N\O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5o,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',8,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',8,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',"0,25",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',4,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',8,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5p,MIC,'=',8,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',4,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',4,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',1,μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,<,"0,5",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',2,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5q,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',8,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',4,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',1,μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',1,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',2,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=O)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5t,MIC,'=',2,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',4,μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',4,μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',1,μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,<,"0,5",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',2,μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',4,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,5u,MIC,'=',4,μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,'=',"0,25",μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,<,"0,125",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,<,"0,125",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,<,"0,125",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,'=',"0,125",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,'=',1,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nncs3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12a,MIC,'=',"0,25",μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,25",μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,25",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,06",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,25",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',2,μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CS(C)(=O)=O)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12b,MIC,'=',"0,5",μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc(CN)s3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12c,MIC,<,"0,5",μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"SA, Staphylococcus aureus UC 9213 (methicillin-susceptible S. aureus)",Staphylococcus aureus,Methicillin susceptible,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"SA, S. aureus UC 12673 (methicillin-resistant S. aureus, Ciprofloxicin resistant, Rifampin resistant, Imipenem resistant)",Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"SE, Staphylococcus epidermis UC 12084 (methicillin-resistant S. epidermis)",Staphylococcus epidermidis,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"SP, Streptococcus pneumoniae UC 9912 (penicillin-sensitive S. pneumoniae)",Streptococcus pneumoniae,Penicillin sensitive,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"EF, Enterococcus faecalis UC 9217 (vancomycin-resistant E. faecalis)",Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"HI, Haemophilus influenzae 30063 (Ampicillin resistant, b-lactamase +)",Haemophilus influenzae,Ampicillin resistant  b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.07.018,CNCc1nnc(-c2ccc(N3C[C@H](CNC(C)=S)OC3=O)cc2F)s1,10.1016/j.bmcl.2003.07.018,"The synthesis and antibacterial activity of 1,3,4-Thiadiazole phenyl oxazolidinone analogues",Elsevier BV,2003,0,12d,MIC,<,"0,5",μg/mL,"MC, Moraxella catarrhalis 30607 (b-lactamase +)",Moraxella catarrhalis,30607 b-lactamase +,3,table 1 (caption),,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(N)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,4,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',4,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NO)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,5,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',4,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,6,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',16,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',8,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',8,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',8,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',4,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC(C)=O)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,7,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=N)NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,8,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',16,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',8,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',8,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',8,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',4,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,9,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',8,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',8,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',8,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',4,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',4,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,10,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',4,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NC4CCCCCC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,11,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,COc1ccc(CNC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)cc1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,12,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',4,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)NCc4ccc(Cl)cc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,13,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,14,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',1,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4cccc(F)c4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,15,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccccc1NC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,16,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,COc1ccc(NC(=O)N2CCN(c3ccc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)CC2)c(OC)c1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,17,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,18,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',2,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',1,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',1,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccc(Cl)cc4Cl)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,19,MIC,'=',2,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,2,table 2,,,,,2,table 2,,,2,table 2,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',4,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',4,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',4,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',2,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',2,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccon4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,20,MIC,'=',4,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',2,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',1,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',1,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4nccs4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,21,MIC,'=',1,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',2,μg/mL,S.a. 035 = Staphylococcus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',2,μg/mL,S.a. 019 = Staphylococcus aureus ATCC 33591 (methicillin resistant),Staphylococcus aureus,Methicillin resistant  ATCC 33591,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',2,μg/mL,S.a. 446 = Staphylococcus aureus (clinical isolate),Staphylococcus aureus,,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',1,μg/mL,E.f. 034 = Enterococcus faecalis ATCC 29212 (vancomycin sensitive),Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',1,μg/mL,E.f. 153 = Enterococcus faecalis NCTC 12201 (vancomycin resistant),Enterococcus faecalis,Vancomycin resistant  NCTC 12201,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.bmcl.2007.09.024,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)Nc4ccccn4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2007.09.024,"Synthesis, SAR, and antibacterial activity of novel oxazolidinone analogues possessing urea functionality",Elsevier BV,2008,0,22,MIC,'=',1,μg/mL,E.fm 154 = Enterococcus faecium ATCC 12202 (vancomycin resistant),Enterococcus faecium,Vancomycin resistant  ATCC 12202,2,table 1 (caption),,,3,table 3,,,,,3,table 3,,,3,table 3,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',2,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',4,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',2,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',1,μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,1,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',1,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',1,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',2,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,2,MIC,'=',4,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',4,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',64,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',4,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',1,μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19a,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',1,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',4,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',"0,25",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19b,MIC,'=',8,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',2,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',32,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',4,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',2,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',1,μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,19c,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',"0,5",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',8,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',"0,5",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,<=,"0,063",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20a,MIC,'=',2,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,125",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',1,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,25",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,125",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,5",μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',"0,063",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20b,MIC,'=',2,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',"0,125",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',2,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',"0,25",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',"0,25",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',"0,063",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,20c,MIC,'=',4,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',2,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',"0,25",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',2,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21a,MIC,'=',4,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',2,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',"0,25",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',"0,25",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,<=,"0,063",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21b,MIC,'=',4,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',2,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',"0,25",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCON(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,21c,MIC,'=',4,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',2,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',4,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',64,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',4,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',4,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',1,μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22a,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',1,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22b,MIC,'=',8,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',2,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',8,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',1,μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,22c,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',64,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',2,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',16,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2ccc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23a,MIC,'=',32,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',"0,5",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',"0,5",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',8,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',"0,25",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',16,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCN1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23b,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',"0,5",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',8,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',"0,25",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C(CO)N1CCN(c2c(F)cc(N3C[C@H](CNc4ccon4)OC3=O)cc2F)CCO1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,23c,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',1,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',"0,25",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,7с,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',4,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',"0,25",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',"0,125",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',"0,063",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,CC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,9c,MIC,'=',2,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',"0,25",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',"0,5",μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',4,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',"0,25",μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',1,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNOCC3)c(F)c2)C(=O)O1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,14c,MIC,'=',8,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',1,μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',2,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',2,μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](Cn2ccnn2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,16c,MIC,'=',8,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',"0,5",μg/mL,Staphylococcus aureus SR20549,Staphylococcus aureus,SR20549,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',1,μg/mL,Staphylococcus aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',16,μg/mL,Linezolid-resistant Staphylococcus aureus NRS271,Staphylococcus aureus,Linezolid resistant  NRS271,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis SR1004,Enterococcus faecalis,SR1004,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',1,μg/mL,Enterococcus faecium SR7940,Enterococcus faecium,SR7940,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',4,μg/mL,Moraxella catarrhalis SR26840,Moraxella catarrhalis,SR26840,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',"0,125",μg/mL,Streptococcus pneumoniae SR26207,Streptococcus pneumoniae,SR26207,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2013.03.003,O=C1O[C@@H](CNc2ccon2)CN1c1cc(F)c(N2CCNOCC2)c(F)c1,10.1016/j.ejmech.2013.03.003,"Antibacterial oxazolidinone analogues having a N-hydroxyacetyl-substituted seven-membered [1,2,5]triazepane or [1,2,5]oxadiazepane C-ring unit",Elsevier BV,2013,0,18c,MIC,'=',16,μg/mL,Haemophilus influenzae SR27914,Haemophilus influenzae,SR27914,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,107399,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,107399,MIC,'=',4,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,107399,MIC,'=',2,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98257,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98257,MIC,'=',2,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98257,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98170,MIC,'=',2,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98170,MIC,'=',2,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COC(=O)N1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98170,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)cc2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,108946,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)cc2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,108946,MIC,'=',2,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)cc2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,108946,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100592,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100592,MIC,'=',1,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100592,MIC,<,"0,5",μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100675,MIC,'=',2,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100675,MIC,'=',1,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100675,MIC,'=',"0,25",μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COc1cc(N2C[C@H](CNC(C)=O)OC2=O)ccc1N1CCN(C(=O)CO)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,143145,MIC,>,16,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COc1cc(N2C[C@H](CNC(C)=O)OC2=O)ccc1N1CCN(C(=O)CO)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,143145,MIC,>,16,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COc1cc(N2C[C@H](CNC(C)=O)OC2=O)ccc1N1CCN(C(=O)CO)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,143145,MIC,>,16,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,97665,MIC,'=',8,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,97665,MIC,'=',4,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,97665,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98172,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98172,MIC,'=',2,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CC#N)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,98172,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99200,MIC,'=',16,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99200,MIC,'=',16,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99200,MIC,'=',2,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99372,MIC,'=',8,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99372,MIC,'=',4,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,COCCN1CCN(c2c(F)cc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)CC1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,99372,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100762,MIC,'=',16,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100762,MIC,'=',8,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100762,MIC,'=',2,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100349,MIC,'=',4,μg/mL,Staphylococcus aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100349,MIC,'=',2,μg/mL,Enterococcus faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
anie.200200528,CC(=O)NC[C@H]1CN(c2cc(F)c(N3CCN(CCF)CC3)c(F)c2)C(=O)O1,10.1002/anie.200200528,Oxazolidinone Structure–Activity Relationships Leading to Linezolid,Wiley,2003,0,100349,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
acs.jmedchem.8b01287,CC(C[C@H]1CN(c2ccc(Br)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13a,MIC,'=',"0,5",μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC(C[C@H]1CN(c2ccc(Br)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13a,MIC,>,64,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC(C[C@H]1CN(c2ccc(Br)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13a,MIC,>,64,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CCCc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13b,MIC,'=',"0,5",μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CCCc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13b,MIC,'=',4,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CCCc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13b,MIC,'=',32,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13c,MIC,'=',2,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13c,MIC,'=',32,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13c,MIC,>,64,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC=Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13d,MIC,'=',1,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC=Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13d,MIC,'=',4,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC=Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13d,MIC,'=',32,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC#Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13e,MIC,'=',"0,5",μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC#Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13e,MIC,'=',2,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC#Cc1ccc(N2C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC2=O)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13e,MIC,'=',16,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C#CC3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13f,MIC,'=',"0,5",μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C#CC3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13f,MIC,'=',"0,125",μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(C#CC3CC3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13f,MIC,'=',1,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13g,MIC,'=',1,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13g,MIC,'=',"0,25",μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cc2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13g,MIC,'=',4,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC(C)(O)C1CC(C#Cc2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)C1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13h,MIC,'=',1,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC(C)(O)C1CC(C#Cc2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)C1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13h,MIC,'=',"0,5",μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,CC(C)(O)C1CC(C#Cc2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)C1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13h,MIC,'=',1,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@H](O)Cc1ccc(-c2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13i,MIC,'=',2,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@H](O)Cc1ccc(-c2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13i,MIC,'=',"0,25",μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@H](O)Cc1ccc(-c2ccc(N3C[C@H](C[C@](C)(C(=O)NO)S(C)(=O)=O)OC3=O)cc2)cc1,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13i,MIC,'=',1,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cn2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13j,MIC,'=',2,μg/mL,P. aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cn2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13j,MIC,'=',2,μg/mL,E. coli ATCC 25922,Escherichia coli,ATCC 25922,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
acs.jmedchem.8b01287,C[C@@](C[C@H]1CN(c2ccc(-c3ccccc3)cn2)C(=O)O1)(C(=O)NO)S(C)(=O)=O,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline",American Chemical Society (ACS),2018,0,13j,MIC,'=',32,μg/mL,K. pneumoniae ATCC 43816,Klebsiella pneumoniae,ATCC 43816,6,table 1 (caption),,,6,table 1,,,,,6,table 1,,,6,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',8,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',4,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,'=',16,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15a,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',1,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,'=',2025-08-04 00:00:00,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,15b,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',8-16,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18a,MIC,'=',32,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',2025-04-02 00:00:00,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',2025-02-01 00:00:00,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',8,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,18b,MIC,'=',16-32,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',8,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,19,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',2025-02-01 00:00:00,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',2025-02-01 00:00:00,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,'=',16,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,22,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2ccc(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25a,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,'=',64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@H]4[CH][C@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,25b,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 1 (caption),,,5,table 1,,,,,5,table 1,,,5,table 1,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(N)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,26,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,'=',16,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CNC(=O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(C)=O)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,27,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',2,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,'=',64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)N(C)C)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,28,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NOCc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,29,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,30,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',2025-04-02 00:00:00,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',"0,5-1",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,36,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',2025-04-02 00:00:00,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,'=',64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(C)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,37,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',16,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',16,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',2,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,'=',64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)CO)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,38,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,'=',32,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NS(C)(=O)=O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,39,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,'=',8,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](NC(=O)Nc5ccccc5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,40,MIC,>,64,μg/mL,E. coli UC6674,Escherichia coli,UC6674,5,table 2 (caption),,,5,table 2,,,,,5,table 2,,,5,table 2,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,'=',1,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,'=',"0,13",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5nccs5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,31,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,COc1ccc(NC(=O)[C]2[C@H]3CN(c4c(F)cc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)C[C@@H]23)cn1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,32,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccco5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,33,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)NCc5ccccn5)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,34,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,'=',1,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,'=',1,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,CC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)Nc5ccc6c(c5)OCO6)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,35,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 3 (caption),,,6,table 3,,,,,6,table 3,,,6,table 3,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,'=',32,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,'=',32,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,'=',16,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,'=',8,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,'=',32,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,43,MIC,>,64,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',4,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',"0,5-1",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',2025-04-02 00:00:00,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](N)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,44,MIC,'=',8-16,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,45,MIC,'=',8,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',4,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',2,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,N[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,46,MIC,'=',4,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',2,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',1,μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',2025-02-01 00:00:00,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,CCC(=O)NC[C@H]1CN(c2cc(F)c(N3C[C@@H]4[C](C(=O)O)[C@@H]4C3)c(F)c2)C(=O)O1,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,49,MIC,'=',8,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',1,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',"0,5",μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',1,μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,50,MIC,'=',4,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',1,μg/mL,Methicillin-susceptible S. aureus UC9213,Staphylococcus aureus,Methicillin susceptible  UC9213,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',"0,5",μg/mL,"Methicillin-, ciprofloxacin-, rifampin-, imipenem-resistant  S. aureus UC12673",Staphylococcus aureus,UC12673,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',"0,5",μg/mL,Penicillin-susceptible S. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm058204j,O=C(O)[C]1[C@H]2CN(c3c(F)cc(N4C[C@H](CNC(=O)C(Cl)Cl)OC4=O)cc3F)C[C@@H]12,10.1021/jm058204j,Conformational Constraint in Oxazolidinone Antibacterials. Synthesis and Structure−Activity Studies of (Azabicyclo[3.1.0]hexylphenyl)oxazolidinones,American Chemical Society (ACS),2005,0,51,MIC,'=',4,μg/mL,Ampicillin-reisitant H. influenzae UC30063,Haemophilus influenzae,UC30063,6,table 4 (caption),,,6,table 4,,,,,6,table 4,,,6,table 4,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',4,μg/mL,Staphyloccocus aureus UC 9213,Staphylococcus aureus,UC 9213,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',2,μg/mL,Staphyloccocus aureus UC 12673,Staphylococcus aureus,UC 12673,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',4,μg/mL,Staphyloccocus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',1,μg/mL,Staphylococcus epidermidis UC 30031,Staphylococcus epidermidis,UC 30031,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',2,μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',1,μg/mL,Enterococcus faecium UC 12712,Enterococcus faecium,UC 12712,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae UC 9912,Streptococcus pneumoniae,UC 9912,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',1,μg/mL,Streptococcus pyogenes UC 152,Streptococcus pyogenes,UC 152,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,>,64,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,>,64,μg/mL,Klebsiella pneumoniae UC 12081,Klebsiella pneumoniae,UC 12081,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,>,64,μg/mL,Pseudomonas aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',1,μg/mL,Bacteroides fragilis ATCC 25285,Bacteroides fragilis,ATCC 25285,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,'=',1,μg/mL,Clostridium perfringens ATCC 13124,Clostridium perfringens,ATCC 13124,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100592,MIC,<=,"0,125",μg/mL,Mycobacterium tuberculosis H37Rv,Mycobacterium tuberculosis,H37Rv,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',4,μg/mL,Staphyloccocus aureus UC 9213,Staphylococcus aureus,UC 9213,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',4,μg/mL,Staphyloccocus aureus UC 12673,Staphylococcus aureus,UC 12673,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',4,μg/mL,Staphyloccocus aureus ATCC 29213,Staphylococcus aureus,ATCC 29213,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',1,μg/mL,Staphylococcus epidermidis UC 30031,Staphylococcus epidermidis,UC 30031,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',4,μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',2,μg/mL,Enterococcus faecium UC 12712,Enterococcus faecium,UC 12712,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',1,μg/mL,Streptococcus pneumoniae UC 9912,Streptococcus pneumoniae,UC 9912,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',2,μg/mL,Streptococcus pyogenes UC 152,Streptococcus pyogenes,UC 152,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,>,64,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,>,64,μg/mL,Klebsiella pneumoniae UC 12081,Klebsiella pneumoniae,UC 12081,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,>,64,μg/mL,Pseudomonas aeruginosa ATCC 27853,Pseudomonas aeruginosa,ATCC 27853,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',1,μg/mL,Bacteroides fragilis ATCC 25285,Bacteroides fragilis,ATCC 25285,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,'=',1,μg/mL,Clostridium perfringens ATCC 13124,Clostridium perfringens,ATCC 13124,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
jm9509556,CC(=O)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1021/jm9509556,"Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections",American Chemical Society (ACS),1996,0,U-100766,MIC,<=,"0,125",μg/mL,Mycobacterium tuberculosis H37Rv,Mycobacterium tuberculosis,H37Rv,3,table 1,,,3,table 1,,,,,3,scheme 1,,,3,scheme 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4a,MIC,'=',"0,78",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4a,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4a,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4a,MIC,'=',"0,39",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4a,MIC,'=',"0,78",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4b,MIC,'=',"0,39",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4b,MIC,'=',"0,39",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4b,MIC,'=',"0,39",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4b,MIC,'=',"0,39",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4b,MIC,'=',"0,39",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4c,MIC,'=',"0,78",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4c,MIC,'=',"0,78",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4c,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4c,MIC,'=',"0,39",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4c,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4d,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4d,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4d,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4d,MIC,'=',"0,78",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4d,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4e,MIC,'=',"6,25",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4e,MIC,'=',"3,13",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4e,MIC,'=',"6,25",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4e,MIC,'=',"6,25",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4e,MIC,'=',"3,13",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,COC1CCN(c2ccc(N3C[C@@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4f,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,COC1CCN(c2ccc(N3C[C@@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4f,MIC,'=',"3,13",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,COC1CCN(c2ccc(N3C[C@@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4f,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,COC1CCN(c2ccc(N3C[C@@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4f,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,COC1CCN(c2ccc(N3C[C@@H](CNC(N)=S)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4f,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4g,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4g,MIC,'=',"0,78",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4g,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4g,MIC,'=',"0,78",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4g,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4h,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4h,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4h,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4h,MIC,'=',"0,78",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4h,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4i,MIC,'=',"12,5",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4i,MIC,'=',50,μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4i,MIC,'=',"12,5",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4i,MIC,'=',"12,5",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4i,MIC,'=',"12,5",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4j,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4j,MIC,'=',"6,25",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4j,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4j,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCS(=O)(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4j,MIC,'=',"0,78",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4k,MIC,'=',"0,78",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4k,MIC,'=',"3,13",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4k,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4k,MIC,'=',"0,39",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4k,MIC,'=',"0,39",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,Cc1cc(N2C[C@H](CNC(N)=S)OC2=O)ccc1N1CCOCC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4l,MIC,'=',"3,13",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,Cc1cc(N2C[C@H](CNC(N)=S)OC2=O)ccc1N1CCOCC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4l,MIC,'=',"3,13",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,Cc1cc(N2C[C@H](CNC(N)=S)OC2=O)ccc1N1CCOCC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4l,MIC,'=',"3,13",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,Cc1cc(N2C[C@H](CNC(N)=S)OC2=O)ccc1N1CCOCC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4l,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,Cc1cc(N2C[C@H](CNC(N)=S)OC2=O)ccc1N1CCOCC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,4l,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,3,MIC,'=',"0,78",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,3,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,3,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,3,MIC,'=',"0,78",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,NC(=S)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,3,MIC,'=',"0,78",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,3,table 1,,,3,table 1,,,,,3,table 1,,,3,table 1,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5a,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5a,MIC,'=',"3,13",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5a,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5a,MIC,'=',"3,13",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5a,MIC,'=',"6,25",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5b,MIC,'=',"6,25",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5b,MIC,'=',"6,25",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5b,MIC,'=',"6,25",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5b,MIC,'=',"6,25",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5b,MIC,'=',"6,25",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@H]1CN(c2ccc(N3CCC(C)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5c,MIC,>,50,μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@H]1CN(c2ccc(N3CCC(C)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5c,MIC,>,50,μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@H]1CN(c2ccc(N3CCC(C)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5c,MIC,>,50,μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@H]1CN(c2ccc(N3CCC(C)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5c,MIC,'=',"12,5",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@H]1CN(c2ccc(N3CCC(C)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5c,MIC,>,50,μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5d,MIC,>,50,μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5d,MIC,>,50,μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5d,MIC,>,50,μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5d,MIC,>,50,μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CCC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5d,MIC,>,50,μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,COC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5e,MIC,'=',"6,25",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,COC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5e,MIC,'=',"6,25",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,COC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5e,MIC,'=',"3,13",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,COC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5e,MIC,'=',"6,25",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,COC1CCN(c2ccc(N3C[C@H](CNC(=S)SC)OC3=O)cc2F)CC1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5e,MIC,'=',"6,25",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5f,MIC,>,50,μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5f,MIC,>,50,μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5f,MIC,>,50,μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5f,MIC,>,50,μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCCCCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5f,MIC,>,50,μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5g,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5g,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5g,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5g,MIC,'=',"0,78",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5g,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5h,MIC,'=',"3,13",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5h,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5h,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5h,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCSCC3)cc2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5h,MIC,'=',"3,13",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5i,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5i,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5i,MIC,'=',"1,56",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5i,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCS(=O)CC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5i,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5j,MIC,'=',"1,56",μg/mL,S. aureus SMITH,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5j,MIC,'=',"1,56",μg/mL,S. aureus HPC1360,Staphylococcus aureus,HPC1360,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5j,MIC,'=',"0,78",μg/mL,S. aureus HPC428,Staphylococcus aureus,HPC428,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5j,MIC,'=',"1,56",μg/mL,E. faecium HPC1322,Enterococcus faecium,HPC1322,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
cpb.49.353,CSC(=S)NC[C@@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,10.1248/cpb.49.353,Structure-Activity Relationship (SAR) Studies on Oxazolidinone Antibacterial Agents. 2. Relationship between Lipophilicity and Antibacterial Activity in 5-Thiocarbonyl Oxazolidinones.,Pharmaceutical Society of Japan,2001,0,5j,MIC,'=',"1,56",μg/mL,E. casseliflavus HPC1310,Enterococcus casseliflavus,HPC1310,4,table 2,,,4,table 2,,,,,4,table 2,,,4,table 2,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,29,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,30,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,31,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,32,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',"0,25",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',"0,25",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,33,MIC,'=',16,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,'=',"0,5",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,'=',"0,5",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,'=',1,μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,'=',1,μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2c(F)cc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cc2F)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,34,MIC,>,128,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,35,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,36,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2COC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,37,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,38,MIC,'=',8,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,39,MIC,>,2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,'=',"0,25",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,'=',"0,5",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CSC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,40,MIC,>,16,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,41,MIC,'=',8,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,42,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,43,MIC,'=',8,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,44,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',"0,06",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,45,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,N#CC1(c2ccc(-c3c(F)cc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CS(=O)(=O)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,46,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,3,table 1 (caption),,,3,table 1,,,,,2,scheme 6a,,,2,scheme 6a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',4,μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',4,μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',4,μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',8,μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',16,μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NCC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,52,MIC,'=',128,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,3,scheme 7a,
jm800800c,NC(=O)C1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,53,MIC,'=',2,μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC(=O)C1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,53,MIC,'=',2,μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC(=O)C1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,53,MIC,'=',1,μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC(=O)C1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,53,MIC,'=',"0,5",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC(=O)C1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,53,MIC,'=',4,μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',1,μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',2,μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',"0,5",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',"0,5",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',2,μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,NC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,54,MIC,'=',32,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 2 (caption),,,4,table 2,,,,,3,scheme 7a,,,,,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,57,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',"0,25",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',"0,25",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CCC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,58,MIC,'=',8,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C(F)F)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,59,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',"0,5",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',"0,25",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',"0,25",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',"0,5",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNC(=O)C5CC5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,60,MIC,'=',8,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',"0,125",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=O)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,61,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',"0,03",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',"0,03",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',"0,06",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,CC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,62,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,03",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,03",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,03",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,03",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,06",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,COC(=S)NC[C@H]1CN(c2ccc(-c3ccc(C4(C#N)[C@@H]5CNC[C@@H]54)nc3)c(F)c2)C(=O)O1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,63,MIC,'=',"0,5",μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,'=',"0,125",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,'=',"0,125",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,'=',"0,25",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,'=',"0,25",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,'=',"0,5",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](CNc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,64,MIC,>,16,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](COc5ccon5)OC4=O)cc3F)cn2)[C@@H]2CNC[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,65,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 3 (caption),,,4,table 3,,,,,3,scheme 8a,,,3,scheme 8a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CC1(c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)[C@@H]2CN(C(=O)CO)C[C@@H]21,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,66,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',"0,06",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,67,MIC,'=',2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',"0,06",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',"0,25",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,CN1C[C@@H]2[C@H](C1)C2(C#N)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,68,MIC,'=',4,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,'=',"0,06",μg/mL,methicillin-sensitive S. aureus Smith,Staphylococcus aureus,Methicillin sensitive  Smith,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,'=',"0,06",μg/mL,methicillin-resistant S. aureus TK7,Staphylococcus aureus,methicillin-resistant  TK7,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,'=',"0,125",μg/mL,penicillin-susceptible S. pneumoniae IID553,Staphylococcus aureus,Penicillin susceptible  IID553,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,'=',"0,06",μg/mL,penicillin-resistant S. pneumoniae PR44,Streptococcus pneumoniae,Penicillin resistant  PR44,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,'=',"0,125",μg/mL,vancomycin-resistant E. faecium A2280,Enterococcus faecium,Vancomycin resistant  A2280,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
jm800800c,N#Cc1ccc(N2C[C@@H]3[C@H](C2)C3(C#N)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)nc1,10.1021/jm800800c,Synthesis and Structure−Activity Relationship Studies of Highly Potent Novel Oxazolidinone Antibacterials,American Chemical Society (ACS),2008,0,69,MIC,>,2,μg/mL,H. influenzae IID983,Haemophilus influenzae,IID983,4,table 4 (caption),,,4,table 4,,,,,3,scheme 9a,,,3,scheme 9a,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',"0,25",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,<=,"0,06",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',"0,25",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',1,μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,<=,"0,06",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',"0,25",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',32,μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',"0,5",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',"0,125",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',"0,25",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',"0,125",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,125",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,<=,"0,06",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,125",μg/mL,S. aureus ATCC 29213 (CIP and LZD susceptible),Staphylococcus aureus,ATCC 29213,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',"0,25",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,'=',1,μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',"0,5",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',"0,5",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,'=',"0,25",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',"0,25",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',16,μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',"0,25",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',"0,125",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',"0,125",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',"0,125",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,125",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,'=',"0,25",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,125",μg/mL,"MRSA, CIP resistant (gyrA: Ser-84-Leu, grlA: Ser-80-Phe)",Staphylococcus aureus,Methicillin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',8,μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,<=,"0,06",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,<=,"0,06",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',"0,5",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,<=,"0,06",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',1,μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',16,μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',"0,5",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',1,μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',1,μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,<=,"0,06",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,125",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,<=,"0,06",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,125",μg/mL,S. aureus LZD resistant (23S rRNA: G2447T),Staphylococcus aureus,LZD resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,<=,"0,06",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',"0,5",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',16,μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',"0,25",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,<=,"0,06",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,06",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,'=',"0,125",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,06",μg/mL,Enterococcus faecalis ATCC 29212,Enterococcus faecalis,ATCC 29212,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',"0,25",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,'=',8,μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',2,μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',2,μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,'=',1,μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',"0,25",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,>,32,μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',"0,5",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',"0,125",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',"0,125",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',"0,25",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,125",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,'=',"0,5",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,125",μg/mL,E. faecium vancomycin and CIP resistant,Enterococcus faecium,Vancomycin resistant,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',1,μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,<=,"0,06",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',"0,125",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',"0,5",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,<=,"0,06",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',1,μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',2,μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',1,μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',"0,5",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,'=',2,μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',"0,125",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',"0,25",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,'=',"0,125",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',"0,5",μg/mL,Haemophilus influenzae 11,Haemophilus influenzae,,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',32,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,'=',"0,5",μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,'=',1,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,'=',8,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,'=',1,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',32,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,>,32,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,'=',8,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,>,32,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,>,32,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,'=',1,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,'=',1,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,'=',1,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,'=',2,μg/mL,Escherichia coli ATCC 25922,Escherichia coli,ATCC 25922,2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3a,MIC,'=',"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(N[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3b,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3c,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3d,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(O[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3e,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3f,MIC,'=',"0,25",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3g,MIC,'=',8,μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC3CCCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3h,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3i,MIC,'=',"0,125",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3j,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3k,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3l,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OC[C@@H]3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3m,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
j.bmcl.2003.07.028,CC(=O)NC[C@H]1CN(c2ccc(OCCC3CCN(c4nc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.07.028,Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action,Elsevier BV,2003,0,3n,MIC,<=,"0,06",μg/mL,"Escherichia coli AS19, permeable mutant",Escherichia coli,"AS19, permeable mutant",2,table 1 (caption),,,2,table 1,,,,,2,table 1,,,2,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,'=',8,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,'=',16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,'=',16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,'=',16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,'=',8,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',8,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',8,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,<=,"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,'=',"0,125",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,<=,"0,125",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,<=,"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,<=,"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,<=,"0,06",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,'=',4,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,<=,"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,'=',"0,25",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,'=',"0,25",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,>,16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,>,16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,'=',2,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',32,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',32,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,3,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,25,MIC,'=',1,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,26,MIC,'=',1,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,27,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,28,MIC,'=',1,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,29,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COC(=O)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,30,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(N)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,31,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)C=Cc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,32,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)CCc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,33,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,34,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(CCCNS(C)(=O)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,35,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,38,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)O)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,39,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(C)=NO)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,40,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CON=C(C)c1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,41,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,4,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CCOC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,47,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,48,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CNC(=O)c1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,49,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,50,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(I)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,54,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(=O)OC(C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,55,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(NC(C)=O)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,56,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#C[Si](C)(C)C)cn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,57,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,C#Cc1cnn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)c1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,58,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C(F)(F)F)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,64,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)OC(C)(C)C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,65,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,66,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(=O)CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,68,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,69,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(NS(C)(=O)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,70,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,71,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,73,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(=O)[nH]3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,77,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccc(OC(C)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,78,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,COc1ccn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,79,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,5,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)c3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,85,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,7,table 1 (caption),,,7,table 1,,,,,7,table 1,,,7,table 1,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,>,16,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,'=',8,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,<=,"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,'=',"0,25",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,<=,"0,125",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,<=,"0,125",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,'=',16,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,>,16,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,'=',4,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,<=,"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',"0,25",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,'=',4,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',2,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,<=,"0,125",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,'=',"0,5",μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,>,16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,>,16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,>,16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,'=',8,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,'=',2,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',4,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',32,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,>,16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ccnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,6,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,87,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(C)=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,88,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,89,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C#N)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,90,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,91,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C(N)=O)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,92,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CNC(=O)c1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,93,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(CO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,94,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cc(C=NO)nn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,95,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CON=Cc1cn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)nn1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,96,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nccn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,7,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,99,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cncn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,8,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,COC(=O)c1ncn(-c2ccc(N3C[C@H](CNC(C)=O)OC3=O)cc2F)n1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,100,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(CO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,101,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,102,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C(N)=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,103,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,104,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(C)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,106,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(NC(=O)Cc4ccccc4)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,>,16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,112,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnc(Cl)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,113,MIC,'=',2,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnc3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,9,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,8,table 2 (caption),,,8,table 2,,,,,8,table 2,,,8,table 2,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',4,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',1,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',2,μg/mL,Methicillin-resistant S. aureus UC6685,Staphylococcus aureus,Methicillin-resistant  UC6685,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',1,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',"0,5",μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',2,μg/mL,Methicillin-resistant S. epidermidis UC12084,Staphylococcus epidermidis,Methicillin-resistant  UC12084,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',"0,5",μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',1,μg/mL,Str. pneumoniae UC9912,Streptococcus pneumoniae,UC9912,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',1,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',16,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',4,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',2,μg/mL,E. faecalis UC9217,Enterococcus faecalis,UC9217,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',8,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',16,μg/mL,H. influenzae UC30063,Haemophilus influenzae,UC30063,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3ncnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,10,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=O)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,116,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C=NO)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,117,MIC,'=',8,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3nnc(C#N)n3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,118,MIC,'=',4,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
jm990373e,CC(=O)NC[C@H]1CN(c2ccc(-n3cnnn3)c(F)c2)C(=O)O1,10.1021/jm990373e,Substituent Effects on the Antibacterial Activity of Nitrogen−Carbon-Linked (Azolylphenyl)oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms <i>Haemophilus </i><i>i</i><i>nfluenzae</i> and <i>Moraxella </i><i>c</i><i>atarrhalis</i>,American Chemical Society (ACS),2000,0,11,MIC,'=',16,μg/mL,M. catarrhalis UC30610,Moraxella catarrhalis,UC30610,9,table 3 (caption),,,9,table 3,,,,,9,table 3,,,9,table 3,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9a,MIC,'=',16,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(C#N)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9b,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,'=',2,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc([N+](=O)[O-])cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9c,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ncccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9d,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,COc1ccc2[nH]cc(C(=O)C(=O)N3CCN(c4ccc(N5C[C@H](CNC(C)=O)OC5=O)cc4F)CC3)c2c1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9e,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,'=',2,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c(C)[nH]c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9f,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,'=',2,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4cn(C)c5ccccc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9g,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,'=',"0,5",μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,9h,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 1 (caption),,,3,table 1,,,,,3,scheme 2,,,3,scheme 2,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',"0,5",μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',"0,25",μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',"0,12",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',"0,25",μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',2,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,'=',2,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,CC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10a,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',"0,5",μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',16,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',32,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,'=',2,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10b,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',1,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',2,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,'=',1,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,COC(=S)NC[C@H]1CN(c2ccc(N3CCN(C(=O)C(=O)c4c[nH]c5ccc(Br)cc45)CC3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10c,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',8,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',2,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',2,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',8,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,'=',4,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C4CC4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10d,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',4,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',"0,25",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',"0,5",μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',4,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,'=',2,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(F)F)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10e,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',1,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',4,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',"0,25",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',"0,5",μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',4,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,'=',2,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](CNC(=O)C(Cl)Cl)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10f,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,4,scheme 3,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',2,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',"0,5",μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',8,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',1,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',"0,5",μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',"0,5",μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',16,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,'=',4,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10g,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,>,32,μg/mL,Staphylococcus aureus DRCC 035 (methicillin-susceptible S. aureus),Staphylococcus aureus,Methicillin susceptible  DRCC 035,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Staphylococcus aureus DRCC 019 (methicillin-resistant S. aureus),Staphylococcus aureus,Methicillin resistant  DRCC 019,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Staphylococcus aureus DRCC 564 (linezolid resistant S. aureus),Staphylococcus aureus,Linezolid resistant  DRCC 564,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Enterococcus faecalis DRCC 034 (vancomycin susceptible E. faecalis),Enterococcus faecalis,Vancomycin susceptible  DRCC 034,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Enterococcus faecalis DRCC 153 (vancomycin-resistant E. faecalis),Enterococcus faecalis,Vancomycin resistant,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,>,32,μg/mL,Enterococcus faecium DRCC154 (vancomycin-resistant E. faecium),Enterococcus faecium,Vancomycin resistant  DRCC154,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Enterococcus faecalis DRCC 632 (linezolid resistant E. faecalis),Enterococcus faecalis,Linezolid resistant  DRCC 632,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,'=',32,μg/mL,Moraxella catarrhalis DRCC 300 (b-lactamase –ve),Moraxella catarrhalis,DRCC 300,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2008.03.043,O=C(C(=O)N1CCN(c2ccc(N3C[C@H](COc4ccon4)OC3=O)cc2F)CC1)c1c[nH]c2ccc(Br)cc12,10.1016/j.bmcl.2008.03.043,Novel and potent oxazolidinone antibacterials featuring 3-indolylglyoxamide substituents,Elsevier BV,2008,0,10h,MIC,>,32,μg/mL,Haemophilus influenzae DRCC 433 (b-lactamase –ve),Haemophilus influenzae,DRCC 433,3,table 2 (caption),,,3,table 2,,,,,4,scheme 3,,,,,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccncc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8b,MIC,'=',1,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccncc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8b,MIC,'=',1,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccncc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8b,MIC,'=',"0,5",μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8c,MIC,'=',"0,5",μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8c,MIC,'=',"0,5",μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8c,MIC,'=',"0,25",μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4ccncc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11a,MIC,'=',1,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4ccncc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11a,MIC,'=',"0,5",μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4ccncc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11a,MIC,'=',"0,5",μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cncnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,12,MIC,'=',1,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cncnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,12,MIC,'=',"0,5",μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cncnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,12,MIC,'=',1,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cccnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11b,MIC,'=',1,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cccnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11b,MIC,'=',1,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(-n3cc4cccnc4c3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,11b,MIC,'=',"0,5",μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8a,MIC,'=',4,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8a,MIC,'=',4,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,8a,MIC,'=',1,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,15,MIC,'=',32,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,15,MIC,'=',8,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,15,MIC,'=',8,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14a,MIC,'=',8,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14a,MIC,'=',8,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14a,MIC,'=',4,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ncccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14b,MIC,'=',16,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ncccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14b,MIC,'=',8,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3Cc4ncccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,14b,MIC,'=',4,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16a,MIC,'=',64,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16a,MIC,'=',32,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccccc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16a,MIC,'=',16,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1ccccn1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17b,MIC,>,128,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1ccccn1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17b,MIC,>,128,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1ccccn1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17b,MIC,>,128,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1cccnc1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17a,MIC,'=',16,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1cccnc1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17a,MIC,'=',16,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CCN(Cc1cccnc1)c1ccc(N2C[C@H](CNC(C)=O)OC2=O)cc1F,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,17a,MIC,'=',8,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccncc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16c,MIC,>,128,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccncc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16c,MIC,>,128,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4ccncc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16c,MIC,>,128,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16b,MIC,>,128,μg/mL,Enterococcus faecalis ATCC 29212 susceptible to vancomycin,Enterococcus faecalis,ATCC 29212,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16b,MIC,>,128,μg/mL,Enterococcus faecium OC 3312 resistant to vancomycin,Enterococcus faecium,Vancomycin resistant  OC 3312,3,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.bmcl.2003.08.031,CC(=O)NC[C@H]1CN(c2ccc(N3C(=O)c4cccnc4C3=O)c(F)c2)C(=O)O1,10.1016/j.bmcl.2003.08.031,Synthesis and antibacterial activity of pyrroloaryl-substituted oxazolidinones,Elsevier BV,2003,0,16b,MIC,>,128,μg/mL,S. aureus OC 2878 is methicillin-resistant (MRSA),Staphylococcus aureus,Methicillin resistant  OC 2878,2,text,,,3,table 1,,,,,3,table 1,,,3,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3a,MIC,'=',"3,25",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4a,MIC,'=',50,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8a,MIC,'=',"0,75",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3b,MIC,'=',"1,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4b,MIC,'=',3,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8b,MIC,'=',"0,75",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3c,MIC,'=',6,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1cccc(N2CC(Cn3sccc3=O)OC2=O)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8c,MIC,'=',50,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3d,MIC,'=',3,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4d,MIC,'=',"0,1",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8d,MIC,'=',"1,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3e,MIC,'=',10,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4e,MIC,'=',6,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8e,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3f,MIC,'=',10,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4f,MIC,'=',"1,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8f,MIC,'=',50,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3g,MIC,'=',25,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4g,MIC,'=',5,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8g,MIC,'=',25,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3h,MIC,'=',25,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4h,MIC,'=',5,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8h,MIC,'=',50,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3i,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4i,MIC,'=',10,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8i,MIC,'=',6,μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3j,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4j,MIC,'=',"0,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8j,MIC,'=',"0,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3k,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4k,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8k,MIC,'=',"12,5",μg/mL,Staphylococcus aureus ATCC 29737,Staphylococcus aureus,ATCC 29737,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3a,MIC,'=',"3,25",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4a,MIC,'=',"0,3",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8a,MIC,'=',"0,75",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3b,MIC,'=',3,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4b,MIC,'=',3,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8b,MIC,'=',"1,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3c,MIC,'=',"3,25",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1cccc(N2CC(Cn3sccc3=O)OC2=O)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8c,MIC,'=',100,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3d,MIC,'=',"1,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4d,MIC,'=',"0,1",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8d,MIC,'=',"1,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3e,MIC,'=',"12,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4e,MIC,'=',10,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8e,MIC,'=',"12,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3f,MIC,'=',3,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4f,MIC,'=',"0,25",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8f,MIC,'=',50,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3g,MIC,'=',2,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4g,MIC,'=',"0,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8g,MIC,'=',25,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3h,MIC,'=',"0,25",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4h,MIC,'=',5,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8h,MIC,'=',100,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3i,MIC,'=',10,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4i,MIC,'=',10,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8i,MIC,'=',"12,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3j,MIC,'=',6,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4j,MIC,'=',"0,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8j,MIC,'=',"0,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3k,MIC,'=',"12,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4k,MIC,'=',"12,5",μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8k,MIC,'=',25,μg/mL,Staphylococcus  epidermidis  ATCC  12229,Staphylococcus epidermidis,ATCC 12229,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3a,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4a,MIC,'=',"0,6",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8a,MIC,'=',"0,01",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3b,MIC,'=',6,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4b,MIC,'=',6,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8b,MIC,'=',"0,75",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3c,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1cccc(N2CC(Cn3sccc3=O)OC2=O)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8c,MIC,'=',100,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3d,MIC,'=',10,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4d,MIC,'=',"0,3",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8d,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3e,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4e,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8e,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3f,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4f,MIC,'=',"1,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8f,MIC,'=',100,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3g,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4g,MIC,'=',5,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8g,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3h,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4h,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8h,MIC,'=',100,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3i,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4i,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8i,MIC,'=',25,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3j,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4j,MIC,'=',"0,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8j,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3k,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4k,MIC,'=',"12,5",μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8k,MIC,'=',50,μg/mL,Escherichia  coli  ATCC  8739,Escherichia coli,ATCC 8739,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3a,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4a,MIC,'=',"0,3",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8a,MIC,'=',"0,01",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3b,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4b,MIC,'=',6,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8b,MIC,'=',"0,75",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3c,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1cccc(N2CC(Cn3sccc3=O)OC2=O)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8c,MIC,'=',100,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3d,MIC,'=',10,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4d,MIC,'=',"0,3",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8d,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3e,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4e,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8e,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3f,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4f,MIC,'=',"1,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8f,MIC,'=',100,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3g,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4g,MIC,'=',5,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8g,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3h,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4h,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8h,MIC,'=',100,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3i,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4i,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8i,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3j,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4j,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8j,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3k,MIC,'=',"12,5",μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4k,MIC,'=',25,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8k,MIC,'=',50,μg/mL,Salmonella  typhimurium  ATCC  1639,Salmonella typhimurium,ATCC 1639,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3a,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4a,MIC,'=',"1,25",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8a,MIC,'=',"0,01",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3b,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4b,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8b,MIC,'=',"0,75",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3c,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1cccc(N2CC(Cn3sccc3=O)OC2=O)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8c,MIC,'=',100,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3d,MIC,'=',10,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4d,MIC,'=',"0,6",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(Cl)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8d,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3e,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4e,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1cccc(Cl)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8e,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3f,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4f,MIC,'=',"0,01",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,COc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8f,MIC,'=',100,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3g,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4g,MIC,'=',"0,01",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,Cc1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8g,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3h,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4h,MIC,'=',"0,1",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(C(F)(F)F)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8h,MIC,'=',100,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3i,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1-c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4i,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8i,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1ccsn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3j,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=c1cc(Cl)sn1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4j,MIC,'=',25,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,O=C1OC(Cn2sccc2=O)CN1Cc1ccccc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8j,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sccc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,3k,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(-n2sc(Cl)cc2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,4k,MIC,'=',"12,5",μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.09.019,CC(=O)c1ccc(N2CC(Cn3sccc3=O)OC2=O)cc1,10.1016/j.ejmech.2009.09.019,Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones,Elsevier BV,2010,0,8k,MIC,'=',100,μg/mL,Pseudomonas  aeruginosa  ATCC  9027,Pseudomonas aeruginosa,ATCC 9027,4,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnc(C)c4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3c,MIC,'=',"1,56",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3g,MIC,'=',"0,78",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cccn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3i,MIC,'=',"0,78",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"0,39",μg/mL,Methicillin-susceptible S. aureus.,Staphylococcus aureus,Methicillin-susceptible .,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"0,39",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"0,39",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnc(C)c4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3c,MIC,'=',"1,56",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn[nH]4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3d,MIC,>,25,μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3g,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ccn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3h,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cccn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3i,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"0,39",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"0,39",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4nnnc4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3l,MIC,'=',"0,78",μg/mL,Methicillin-resistant S. aureus.,Staphylococcus aureus,Methicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnc(C)c4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3c,MIC,'=',"0,39",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn[nH]4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3d,MIC,'=',25,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"0,39",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3g,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ccn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3h,MIC,'=',"0,39",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cccn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3i,MIC,'=',"0,39",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"0,2",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4nnnc4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3l,MIC,'=',"0,39",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"0,2",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"0,2",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"0,2",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"0,2",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"0,1",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"0,1",μg/mL,Penicillin-resistant Streptococcus pneumoniae,Streptococcus pneumoniae,Penicillin resistant,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cccn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3i,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"1,56",μg/mL,Moraxella catarrhalis,Moraxella catarrhalis,UC30610,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnc4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3a,MIC,'=',"6,25",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cncn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3b,MIC,'=',"6,25",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnc(C)c4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3c,MIC,>,25,μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ncon4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3e,MIC,'=',"6,25",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnnn4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3f,MIC,'=',"3,13",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4nnn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3g,MIC,'=',"6,25",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-c4ccn(C)n4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3h,MIC,'=',50,μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cccn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3i,MIC,'=',45058,μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4ccnn4)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3j,MIC,'=',"3,13",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4cnnn4)nc3)cc2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3k,MIC,'=',"6,25",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.bmc.2004.08.025,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc(-n4nnnc4C)nc3)c(F)c2)C(=O)O1,10.1016/j.bmc.2004.08.025,Synthesis and antibacterial activity of oxazolidinones containing pyridine substituted with heteroaromatic ring,Elsevier BV,2004,0,3l,MIC,'=',"3,13",μg/mL,Haemophilus inﬂuenzae,Haemophilus influenzae,,3,table 1 (caption),,,3,table 1,,,,,2,scheme 1,,,2,scheme 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-08-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-08-04 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-08-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',8,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)OC(C)(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,15,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C=O)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17a,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-02-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17b,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-04-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(F)(F)F)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17c,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-02-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',2025-04-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17d,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',1,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',1,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',1,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17e,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCOC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17f,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-04-02 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCSC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17g,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',"0,5-2",μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(Cl)Cl)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17h,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',1,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',1,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',"0,5-1",μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',2,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',1,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17i,MIC,'=',"0,5-1",μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-04-02 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17j,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',2,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC(C)C)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17k,MIC,'=',4,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',2,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',4,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCC(C)C(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17l,MIC,'=',4,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,>,64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',2,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',8,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17m,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',8,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,>,64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',8,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',8,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',2025-08-04 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',8,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',8-16,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',4,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,CCCCCCC(=O)N1CCN(c2ccc(N3C[C@H](Cn4cc(C)nn4)OC3=O)cc2F)CC1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17n,MIC,'=',4,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2025-04-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17o,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17p,MIC,'=',2,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17q,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-08-04 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C5CCCCC5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17r,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',1,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',1,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',4,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',1,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)c5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17s,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,>,64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17t,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',16,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,>,64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',16,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8-16,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8-16,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8-16,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8-16,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)C=Cc5ccccc5)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17u,MIC,'=',8,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,>,64,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',2025-04-02 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',16-32,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',2025-04-02 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCN(C(=O)CC5CC6CCC5C6)CC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,17v,MIC,'=',2,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,4,table 1,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',32,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',2025-08-04 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',4,μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',4,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',2025-08-04 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',2,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',2025-08-04 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCNCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,16,MIC,'=',8,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',4,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',"0,5-2",μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2025-02-01 00:00:00,μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2025-02-01 00:00:00,μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',2025-02-01 00:00:00,μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,Cc1cn(C[C@H]2CN(c3ccc(N4CCOCC4)c(F)c3)C(=O)O2)nn1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,10,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',1,μg/mL,Staphylococcus aureus ATCC 25923 + no plasma,Staphylococcus aureus,ATCC 25923,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',1,μg/mL,Staphylococcus aureus ATCC 25923 + 50% plasma,Staphylococcus aureus,ATCC 25923 + 50% plasma,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5-1",μg/mL,Methicillin-susceptible Staphylococcus aureus,Staphylococcus aureus,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant Staphylococcus aureus,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5-1",μg/mL,Methicillin-susceptible coagulase-negative staphylococci,Staphylococci,Methicillin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5-1",μg/mL,Methicillin-resistant coagulase-negative staphylococci,Staphylococcus aureus,Methicillin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5",μg/mL,Streptococcus pneumoniae,Streptococcus pneumoniae,,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',"0,5-1",μg/mL,Vancomycin-susceptible enterococci,Enterococci,Vancomycin susceptible,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
j.ejmech.2009.03.024,O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(N2CCOCC2)c(F)c1,10.1016/j.ejmech.2009.03.024,"Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones",Elsevier BV,2009,0,PH-027,MIC,'=',1,μg/mL,Vancomycin-resistant enterococci,Enterococci,Vancomycin resistant,5,table 1 (caption),,,4,table 1,,,,,4,table 1,,,,,
